XML 52 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Deficit) (Tables)
12 Months Ended
Dec. 31, 2018
Equity [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:
 
Year Ended December 31,
 
2018
 
2017
Volatility
57.76%
 
—%
Risk-free interest rate
2.65%
 
—%
Expected life in years
6.24
 
Dividend yield rate
—%
 
—%
Share-based Compensation, Stock Options, Activity
A summary of the status of the Company’s nonvested options as of and changes during the year ended December 31, 2018, are presented below:
 
 
 
Weighted-Average
 
Stock
 
Grant Date
 
Options
 
Fair Value
Outstanding, December 31, 2017
 
$

Granted
3,840,724
 
11.68

Cancelled/forfeited
(582,923)
 
9.98

Outstanding, December 31, 2018
3,257,801
 
$
11.99

A summary of stock option activity under the Plan for the year ended December 31, 2018, is presented below:
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted
 
 
 
 
 
Weighted
 
Average
 
Aggregate
 
 
 
Average
 
Remaining
 
Intrinsic
 
Stock
 
Exercise
 
Contractual
 
Value
 
Options
 
Per Share
 
Terms (Years)
 
(in thousands)
Outstanding, December 31, 2017
 
$

 
 
$

Granted
3,840,724
 
11.68

 
9.33
 
8,632

Exercised
 

 
 

Cancelled/forfeited
(582,923)
 
9.98

 
9.02
 
(1,513
)
Outstanding, December 31, 2018
3,257,801
 
$
11.99

 
9.26
 
$
7,119

Exercisable, December 31, 2018
 
$

 
 
$

Schedule of Share-based Compensation, Restricted Stock Units Award Activity
A summary of restricted stock unit activity under the Plan for the year ended December 31, 2018, is presented below:
 
 
 
 
 
 
 
Weighted
 
Restricted
 
Average
 
Stock
 
Grant Date
 
Units
 
Fair Value
Outstanding, December 31, 2017
 
$

Granted
321,516
 
14.38

Vested
(34,602)
 
9.98

Forfeited
(15,510)
 
9.98

Outstanding, December 31, 2018
271,404
 
$
15.19

Schedule of stock-based compensation expense allocation
The following table summarizes stock-based compensation expense (in thousands) amounts recorded in the accompanying statements of operations and comprehensive loss pursuant to the Plan in 2018 and allocated to Evolus by ALPHAEON in 2017:
 
Year Ended December 31,
 
2018
 
2017
General and administrative
$
5,570

 
$
551

Research and development
1,401

 
35

 
$
6,971

 
$
586